Heterozygous familial hypercholesterolemia (HeFH) is caused by mutations in the LDL receptor gene, resulting in unusually high levels of low-density lipoprotein (LDL-C) in serum. Researchers from Epigenic Therapeutics Co. Ltd. presented the discovery of an epigenetic modulation therapeutic, EPI-001, for HeFH.
Vyne Therapeutics Inc. has released promising new preclinical data on its oral small-molecule BD2-selective BET inhibitor, VYN-202, in preclinical models of psoriasis and rheumatoid arthritis. In a well-established model, a psoriasis phenotype was induced in BALB-C mice, and treatment was administered intraperitoneally with either VYN-202, the allosteric TYK2 inhibitor Sotykto (deucravacitinib, Bristol Myers Squibb Co.) or placebo.
During the IDWeek conference held in Boston earlier this month, presentations on Climate Change were spread throughout the program. Some talks were on the direct effects of weather on infectious agents. Others discussed what healthcare workers could do to mitigate the effects of climate change, from antibiotic stewardship to decarbonization of day to day operations.
A Hangzhou Highlightll Pharmaceutical Co. Ltd. patent describes new NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, inflammation, liver and metabolic disease, neuroinflammation, immunological, cardiovascular and renal disorders.
Yiteng Pharmaceutical Industry (Taizhou) Co. Ltd. has disclosed new inhibitors of cyclin-dependent kinase (CDK), particularly CDK7, reported to be useful for the treatment of cancer.
Indolinone derivatives acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors are detailed in a recent Chengdu Baiyu Pharmaceutical Co. Ltd. patent and described as potentially useful for the treatment of cancer.
FL2022-001 Inc. has patented new 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) inhibitors reported to be useful for the treatment of liver fibrosis and nonalcoholic steatohepatitis.
Work at Praxis Precision Medicines Inc. has led to the identification of new compounds comprising an azaspiroheptane and acting as T-type calcium channel blockers, particularly voltage-dependent T-type calcium channel subunit α-1G (Cav3.1) blockers. As such, they are reported to be useful for the treatment of essential tremor.
Protein bromodomain-containing protein 4 (BRD4) is involved in transcription, DNA replication and cell cycle among other processes, and its overexpression has been linked to several types of cancer and immune disorders.